News

Filter

Current filters:

Neulasta

1 to 9 of 51 results

Cost-cutting helps Amgen lift 3rd quarter 2009 EPS 21%

22-10-2009

Leading US biotechnology firm reported adjusted earnings per share of $1.49 for the third quarter of…

AmgenAranespBiotechnologyDarbepoetin AlfaEnbrelEpoetin AlfaEpogenetanerceptFilgrastimFinancialNeulastaNeupogenpegfilgrastimProcrit

Under pressure from Congress, Amgen backs down on controversial drug-pricing

08-09-2008

US biotechnology giant Amgen is to abandon pricing practices on several of its leading drugs from October…

AmgenAranespDarbepoetin AlfaEpoetin AlfaEpogenFilgrastimJohnson & JohnsonNeulastaNeupogenpegfilgrastimProcrit

1 to 9 of 51 results

Back to top